Peanut allergy immunotherapy - Inimmune Corporation/Intrommune Therapeutics
Latest Information Update: 19 Feb 2024
At a glance
- Originator Inimmune; Intrommune Therapeutics
- Class Antiallergics; Food allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Peanut hypersensitivity
Most Recent Events
- 11 Jan 2024 Early research in Peanut hypersensitivity in USA (PO) prior to January 2024
- 08 Jan 2024 Inimmune Corporation and Intrommune Therapeutics collaborate to develop peanut allergy immunotherapy for Peanut hypersensitivity
- 08 Jan 2024 Inimmune Corporation and Intrommune Therapeutics plan clinical trials in Peanut hypersensitivity